Global Anti-obesity Drugs Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	166 Pages	TechNavio	May, 2024	INF18930208

Best Price Guarantee
Price	from $2,500
Length	166 Pages
Publisher	TechNavio
Published Date	May, 2024
SKU	INF18930208

Global Anti-Obesity Drugs Market 2024-2028

Technavio has been monitoring the anti-obesity drugs market and is forecast to grow by USD 18330.1 mn during 2023-2028, accelerating at a CAGR of 14.44% during the forecast period. Our report on the anti-obesity drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing obese population, use of bariatric surgery limited for morbid obesity, and limited number of approved drugs.

Technavio's anti-obesity drugs market is segmented as below:

By Type

Class III anti-obesity drugs
Class II anti-obesity drugs
Class I anti-obesity drugs

By Drug Class

Peripherally acting drugs
Centrally acting drugs

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the research on drugs that target both obesity and type 2 diabetes mellitus as one of the prime reasons driving the anti-obesity drugs market growth during the next few years. Also, awareness about weight management and increase in childhood obesity and morbid obesity incidence will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the anti-obesity drugs market covers the following areas:

Anti-obesity drugs market sizing
Anti-obesity drugs market forecast
Anti-obesity drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-obesity drugs market vendors that include Alvogen Iceland ehf, Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Empros Pharma AB, ERX Pharmaceuticals Inc., Gelesis Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., LG Chem Ltd., Novo Nordisk AS, Rhythm Pharmaceuticals Inc., SCOHIA PHARMA Inc., VIVUS LLC, and Zydus Lifesciences Ltd.. Also, the anti-obesity drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market by Geography; Executive Summary - Chart on Market Segmentation by Type; Executive Summary - Chart on Market Segmentation by Drug Class; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 2.2 Market characteristics; Market characteristics analysis; 2.3 Value chain analysis; Value Chain Analysis
3 Market Sizing: 3.1 Market definition; Offerings of companies included in the market definition; 3.2 Market segment analysis; Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Chart on Global - Market size and forecast 2023-2028 ($ million); Data Table on Global - Market size and forecast 2023-2028 ($ million); Chart on Global Market: Year-over-year growth 2023-2028 (%); Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global Anti-Obesity Drugs Market 2018 - 2022; Historic Market Size - Data Table on Global Anti-Obesity Drugs Market 2018 - 2022 ($ million); 4.2 Type segment analysis 2018 - 2022; Historic Market Size - Type Segment 2018 - 2022 ($ million); 4.3 Drug Class segment analysis 2018 - 2022; Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); 4.4 Geography segment analysis 2018 - 2022; Historic Market Size - Geography Segment 2018 - 2022 ($ million); 4.5 Country segment analysis 2018 - 2022; Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type: 6.1 Market segments; Chart on Type - Market share 2023-2028 (%); Data Table on Type - Market share 2023-2028 (%); 6.2 Comparison by Type; Chart on Comparison by Type; Data Table on Comparison by Type; 6.3 Class III anti-obesity drugs - Market size and forecast 2023-2028; Chart on Class III anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Data Table on Class III anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Chart on Class III anti-obesity drugs - Year-over-year growth 2023-2028 (%); Data Table on Class III anti-obesity drugs - Year-over-year growth 2023-2028 (%); 6.4 Class II anti-obesity drugs - Market size and forecast 2023-2028; Chart on Class II anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Data Table on Class II anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Chart on Class II anti-obesity drugs - Year-over-year growth 2023-2028 (%); Data Table on Class II anti-obesity drugs - Year-over-year growth 2023-2028 (%); 6.5 Class I anti-obesity drugs - Market size and forecast 2023-2028; Chart on Class I anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Data Table on Class I anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Chart on Class I anti-obesity drugs - Year-over-year growth 2023-2028 (%); Data Table on Class I anti-obesity drugs - Year-over-year growth 2023-2028 (%); 6.6 Market opportunity by Type; Market opportunity by Type ($ million); Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Drug Class: 7.1 Market segments; Chart on Drug Class - Market share 2023-2028 (%); Data Table on Drug Class - Market share 2023-2028 (%); 7.2 Comparison by Drug Class; Chart on Comparison by Drug Class; Data Table on Comparison by Drug Class; 7.3 Peripherally acting drugs - Market size and forecast 2023-2028; Chart on Peripherally acting drugs - Market size and forecast 2023-2028 ($ million); Data Table on Peripherally acting drugs - Market size and forecast 2023-2028 ($ million); Chart on Peripherally acting drugs - Year-over-year growth 2023-2028 (%); Data Table on Peripherally acting drugs - Year-over-year growth 2023-2028 (%); 7.4 Centrally acting drugs - Market size and forecast 2023-2028; Chart on Centrally acting drugs - Market size and forecast 2023-2028 ($ million); Data Table on Centrally acting drugs - Market size and forecast 2023-2028 ($ million); Chart on Centrally acting drugs - Year-over-year growth 2023-2028 (%); Data Table on Centrally acting drugs - Year-over-year growth 2023-2028 (%); 7.5 Market opportunity by Drug Class; Market opportunity by Drug Class ($ million); Data Table on Market opportunity by Drug Class ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Chart on Market share By Geographical Landscape2023-2028 (%); Data Table on Market share By Geographical Landscape2023-2028 (%); 9.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Chart on North America - Market size and forecast 2023-2028 ($ million); Data Table on North America - Market size and forecast 2023-2028 ($ million); Chart on North America - Year-over-year growth 2023-2028 (%); Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Chart on Europe - Market size and forecast 2023-2028 ($ million); Data Table on Europe - Market size and forecast 2023-2028 ($ million); Chart on Europe - Year-over-year growth 2023-2028 (%); Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Chart on Asia - Market size and forecast 2023-2028 ($ million); Data Table on Asia - Market size and forecast 2023-2028 ($ million); Chart on Asia - Year-over-year growth 2023-2028 (%); Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Chart on US - Market size and forecast 2023-2028 ($ million); Data Table on US - Market size and forecast 2023-2028 ($ million); Chart on US - Year-over-year growth 2023-2028 (%); Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 Germany - Market size and forecast 2023-2028; Chart on Germany - Market size and forecast 2023-2028 ($ million); Data Table on Germany - Market size and forecast 2023-2028 ($ million); Chart on Germany - Year-over-year growth 2023-2028 (%); Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.9 UK - Market size and forecast 2023-2028; Chart on UK - Market size and forecast 2023-2028 ($ million); Data Table on UK - Market size and forecast 2023-2028 ($ million); Chart on UK - Year-over-year growth 2023-2028 (%); Data Table on UK - Year-over-year growth 2023-2028 (%); 9.10 Canada - Market size and forecast 2023-2028; Chart on Canada - Market size and forecast 2023-2028 ($ million); Data Table on Canada - Market size and forecast 2023-2028 ($ million); Chart on Canada - Year-over-year growth 2023-2028 (%); Data Table on Canada - Year-over-year growth 2023-2028 (%); 9.11 China - Market size and forecast 2023-2028; Chart on China - Market size and forecast 2023-2028 ($ million); Data Table on China - Market size and forecast 2023-2028 ($ million); Chart on China - Year-over-year growth 2023-2028 (%); Data Table on China - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity by geography; Market opportunity By Geographical Landscape($ million); Data Tables on Market opportunity By Geographical Landscape($ million)
10 Drivers, Challenges, and Opportunity/Restraints: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Impact of drivers and challenges in 2023 and 2028; 10.4 Market opportunities/restraints
11 Competitive Landscape: 11.1 Overview; 11.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 11.3 Landscape disruption; Overview on factors of disruption; 11.4 Industry risks; Impact of key risks on business
12 Competitive Analysis: 12.1 Companies profiled; Companies covered; 12.2 Market positioning of companies; Matrix on companies position and classification; 12.3 Alvogen Iceland ehf; Alvogen Iceland ehf - Overview; Alvogen Iceland ehf - Product / Service; Alvogen Iceland ehf - Key offerings; 12.4 AstraZeneca Plc; AstraZeneca Plc - Overview; AstraZeneca Plc - Product / Service; AstraZeneca Plc - Key news; AstraZeneca Plc - Key offerings; 12.5 Boehringer Ingelheim International GmbH; Boehringer Ingelheim International GmbH - Overview; Boehringer Ingelheim International GmbH - Product / Service; Boehringer Ingelheim International GmbH - Key news; Boehringer Ingelheim International GmbH - Key offerings; 12.6 Eli Lilly and Co.; Eli Lilly and Co. - Overview; Eli Lilly and Co. - Product / Service; Eli Lilly and Co. - Key news; Eli Lilly and Co. - Key offerings; 12.7 Empros Pharma AB; Empros Pharma AB - Overview; Empros Pharma AB - Product / Service; Empros Pharma AB - Key offerings; 12.8 ERX Pharmaceuticals Inc.; ERX Pharmaceuticals Inc. - Overview; ERX Pharmaceuticals Inc. - Product / Service; ERX Pharmaceuticals Inc. - Key offerings; 12.9 Gelesis Inc.; Gelesis Inc. - Overview; Gelesis Inc. - Product / Service; Gelesis Inc. - Key offerings; 12.10 GlaxoSmithKline Plc; GlaxoSmithKline Plc - Overview; GlaxoSmithKline Plc - Business segments; GlaxoSmithKline Plc - Key news; GlaxoSmithKline Plc - Key offerings; GlaxoSmithKline Plc - Segment focus; 12.11 Innovent Biologics Inc.; Innovent Biologics Inc. - Overview; Innovent Biologics Inc. - Product / Service; Innovent Biologics Inc. - Key offerings; 12.12 LG Chem Ltd.; LG Chem Ltd. - Overview; LG Chem Ltd. - Business segments; LG Chem Ltd. - Key news; LG Chem Ltd. - Key offerings; LG Chem Ltd. - Segment focus; 12.13 Novo Nordisk AS; Novo Nordisk AS - Overview; Novo Nordisk AS - Business segments; Novo Nordisk AS - Key news; Novo Nordisk AS - Key offerings; Novo Nordisk AS - Segment focus; 12.14 Rhythm Pharmaceuticals Inc.; Rhythm Pharmaceuticals Inc. - Overview; Rhythm Pharmaceuticals Inc. - Product / Service; Rhythm Pharmaceuticals Inc. - Key news; Rhythm Pharmaceuticals Inc. - Key offerings; 12.15 SCOHIA PHARMA Inc.; SCOHIA PHARMA Inc. - Overview; SCOHIA PHARMA Inc. - Product / Service; SCOHIA PHARMA Inc. - Key news; SCOHIA PHARMA Inc. - Key offerings; 12.16 VIVUS LLC; VIVUS LLC - Overview; VIVUS LLC - Product / Service; VIVUS LLC - Key offerings; 12.17 Zydus Lifesciences Ltd.; Zydus Lifesciences Ltd. - Overview; Zydus Lifesciences Ltd. - Business segments; Zydus Lifesciences Ltd. - Key news; Zydus Lifesciences Ltd. - Key offerings; Zydus Lifesciences Ltd. - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 13.3 Currency conversion rates for US$; Currency conversion rates for US$; 13.4 Research methodology; Research methodology; 13.5 Data procurement; Information sources; 13.6 Data validation; Data validation; 13.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 13.8 Data synthesis; Data synthesis; 13.9 market analysis; market analysis; 13.10 List of abbreviations; List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market by Geography; Exhibits5: Executive Summary - Chart on Market Segmentation by Type; Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Company Market Positioning; Exhibits10: Parent Market; Exhibits11: Data Table on - Parent Market; Exhibits12: Market characteristics analysis; Exhibits13: Value Chain Analysis; Exhibits14: Offerings of companies included in the market definition; Exhibits15: Market segments; Exhibits16: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibits17: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibits18: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits19: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits20: Historic Market Size - Data Table on Global Anti-Obesity Drugs Market 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Type Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); Exhibits23: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits24: Historic Market Size - Country Segment 2018 - 2022 ($ million); Exhibits25: Five forces analysis - Comparison between 2023 and 2028; Exhibits26: Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits27: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits28: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits29: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits30: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits31: Chart on Market condition - Five forces 2023 and 2028; Exhibits32: Chart on Type - Market share 2023-2028 (%); Exhibits33: Data Table on Type - Market share 2023-2028 (%); Exhibits34: Chart on Comparison by Type; Exhibits35: Data Table on Comparison by Type; Exhibits36: Chart on Class III anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Exhibits37: Data Table on Class III anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Exhibits38: Chart on Class III anti-obesity drugs - Year-over-year growth 2023-2028 (%); Exhibits39: Data Table on Class III anti-obesity drugs - Year-over-year growth 2023-2028 (%); Exhibits40: Chart on Class II anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Exhibits41: Data Table on Class II anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Exhibits42: Chart on Class II anti-obesity drugs - Year-over-year growth 2023-2028 (%); Exhibits43: Data Table on Class II anti-obesity drugs - Year-over-year growth 2023-2028 (%); Exhibits44: Chart on Class I anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Exhibits45: Data Table on Class I anti-obesity drugs - Market size and forecast 2023-2028 ($ million); Exhibits46: Chart on Class I anti-obesity drugs - Year-over-year growth 2023-2028 (%); Exhibits47: Data Table on Class I anti-obesity drugs - Year-over-year growth 2023-2028 (%); Exhibits48: Market opportunity by Type ($ million); Exhibits49: Data Table on Market opportunity by Type ($ million); Exhibits50: Chart on Drug Class - Market share 2023-2028 (%); Exhibits51: Data Table on Drug Class - Market share 2023-2028 (%); Exhibits52: Chart on Comparison by Drug Class; Exhibits53: Data Table on Comparison by Drug Class; Exhibits54: Chart on Peripherally acting drugs - Market size and forecast 2023-2028 ($ million); Exhibits55: Data Table on Peripherally acting drugs - Market size and forecast 2023-2028 ($ million); Exhibits56: Chart on Peripherally acting drugs - Year-over-year growth 2023-2028 (%); Exhibits57: Data Table on Peripherally acting drugs - Year-over-year growth 2023-2028 (%); Exhibits58: Chart on Centrally acting drugs - Market size and forecast 2023-2028 ($ million); Exhibits59: Data Table on Centrally acting drugs - Market size and forecast 2023-2028 ($ million); Exhibits60: Chart on Centrally acting drugs - Year-over-year growth 2023-2028 (%); Exhibits61: Data Table on Centrally acting drugs - Year-over-year growth 2023-2028 (%); Exhibits62: Market opportunity by Drug Class ($ million); Exhibits63: Data Table on Market opportunity by Drug Class ($ million); Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits65: Chart on Market share By Geographical Landscape2023-2028 (%); Exhibits66: Data Table on Market share By Geographical Landscape2023-2028 (%); Exhibits67: Chart on Geographic comparison; Exhibits68: Data Table on Geographic comparison; Exhibits69: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibits70: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibits71: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits72: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits73: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibits74: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibits75: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits76: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits77: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibits78: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibits79: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits80: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits81: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits82: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits83: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits84: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits85: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits86: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits87: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits88: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits89: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibits90: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibits91: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits92: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits93: Chart on UK - Market size and forecast 2023-2028 ($ million); Exhibits94: Data Table on UK - Market size and forecast 2023-2028 ($ million); Exhibits95: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits96: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits97: Chart on Canada - Market size and forecast 2023-2028 ($ million); Exhibits98: Data Table on Canada - Market size and forecast 2023-2028 ($ million); Exhibits99: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits100: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits101: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibits102: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibits103: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits104: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits105: Market opportunity By Geographical Landscape($ million); Exhibits106: Data Tables on Market opportunity By Geographical Landscape($ million); Exhibits107: Impact of drivers and challenges in 2023 and 2028; Exhibits108: Overview on criticality of inputs and factors of differentiation; Exhibits109: Overview on factors of disruption; Exhibits110: Impact of key risks on business; Exhibits111: Companies covered; Exhibits112: Matrix on companies position and classification; Exhibits113: Alvogen Iceland ehf - Overview; Exhibits114: Alvogen Iceland ehf - Product / Service; Exhibits115: Alvogen Iceland ehf - Key offerings; Exhibits116: AstraZeneca Plc - Overview; Exhibits117: AstraZeneca Plc - Product / Service; Exhibits118: AstraZeneca Plc - Key news; Exhibits119: AstraZeneca Plc - Key offerings; Exhibits120: Boehringer Ingelheim International GmbH - Overview; Exhibits121: Boehringer Ingelheim International GmbH - Product / Service; Exhibits122: Boehringer Ingelheim International GmbH - Key news; Exhibits123: Boehringer Ingelheim International GmbH - Key offerings; Exhibits124: Eli Lilly and Co. - Overview; Exhibits125: Eli Lilly and Co. - Product / Service; Exhibits126: Eli Lilly and Co. - Key news; Exhibits127: Eli Lilly and Co. - Key offerings; Exhibits128: Empros Pharma AB - Overview; Exhibits129: Empros Pharma AB - Product / Service; Exhibits130: Empros Pharma AB - Key offerings; Exhibits131: ERX Pharmaceuticals Inc. - Overview; Exhibits132: ERX Pharmaceuticals Inc. - Product / Service; Exhibits133: ERX Pharmaceuticals Inc. - Key offerings; Exhibits134: Gelesis Inc. - Overview; Exhibits135: Gelesis Inc. - Product / Service; Exhibits136: Gelesis Inc. - Key offerings; Exhibits137: GlaxoSmithKline Plc - Overview; Exhibits138: GlaxoSmithKline Plc - Business segments; Exhibits139: GlaxoSmithKline Plc - Key news; Exhibits140: GlaxoSmithKline Plc - Key offerings; Exhibits141: GlaxoSmithKline Plc - Segment focus; Exhibits142: Innovent Biologics Inc. - Overview; Exhibits143: Innovent Biologics Inc. - Product / Service; Exhibits144: Innovent Biologics Inc. - Key offerings; Exhibits145: LG Chem Ltd. - Overview; Exhibits146: LG Chem Ltd. - Business segments; Exhibits147: LG Chem Ltd. - Key news; Exhibits148: LG Chem Ltd. - Key offerings; Exhibits149: LG Chem Ltd. - Segment focus; Exhibits150: Novo Nordisk AS - Overview; Exhibits151: Novo Nordisk AS - Business segments; Exhibits152: Novo Nordisk AS - Key news; Exhibits153: Novo Nordisk AS - Key offerings; Exhibits154: Novo Nordisk AS - Segment focus; Exhibits155: Rhythm Pharmaceuticals Inc. - Overview; Exhibits156: Rhythm Pharmaceuticals Inc. - Product / Service; Exhibits157: Rhythm Pharmaceuticals Inc. - Key news; Exhibits158: Rhythm Pharmaceuticals Inc. - Key offerings; Exhibits159: SCOHIA PHARMA Inc. - Overview; Exhibits160: SCOHIA PHARMA Inc. - Product / Service; Exhibits161: SCOHIA PHARMA Inc. - Key news; Exhibits162: SCOHIA PHARMA Inc. - Key offerings; Exhibits163: VIVUS LLC - Overview; Exhibits164: VIVUS LLC - Product / Service; Exhibits165: VIVUS LLC - Key offerings; Exhibits166: Zydus Lifesciences Ltd. - Overview; Exhibits167: Zydus Lifesciences Ltd. - Business segments; Exhibits168: Zydus Lifesciences Ltd. - Key news; Exhibits169: Zydus Lifesciences Ltd. - Key offerings; Exhibits170: Zydus Lifesciences Ltd. - Segment focus; Exhibits171: Inclusions checklist; Exhibits172: Exclusions checklist; Exhibits173: Currency conversion rates for US$; Exhibits174: Research methodology; Exhibits175: Information sources; Exhibits176: Data validation; Exhibits177: Validation techniques employed for market sizing; Exhibits178: Data synthesis; Exhibits179: 360 degree market analysis; Exhibits180: List of abbreviations